1422431-55-7

Upstream product

• 77-78-1 dimethyl sulfate 
• 63909-38-6 3-methoxy-4-benzyloxy-ω-nitrostyrolene 
• 4697-59-0 7,8-dimethoxyisochroman-3-one 
• 56201-87-7 8-hydroxy-7-methoxyisobenzofuranyltetrahydropyran-3-one 
• 1131-94-8 homoisovanillic acid 
• 100-39-0 benzyl bromide 
• 121-33-5 vanillin 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 22231-61-4 2-[4-(benzyloxy)-3-methoxyphenyl]ethylamine 
• 1429118-77-3 (S)-(6-((7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-2,3-dimethoxyphenyl)methanol 
• 1422431-47-7 (S)-6-((7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-2,3-dimethoxybenzyl acetate 
• 1422431-39-7 6-((7-(benzyloxy)-6-methoxy-3,4-dihydroisoquinolin-1-yl)methyl)-2,3-dimethoxybenzyl acetate 

Downstream Products

• 6487-33-8 (-)-isocorypalmine 

Relevant academic research and scientific papers

TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION

The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile

An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D1, D2 and serotonin 5-HT 1A and 5-HT2A receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D1 receptor with Ki values of 50 and 6.3 nM, while both compounds act as D2 receptor antagonists (Ki = 305 and 145 nM, respectively) and 5-HT1A receptor full agonists (Ki = 149 and 908 nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT1A receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.